<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">CHAMBERLAIN, FLORENCE</style></author><author><style face="normal" font="default" size="100%">ENGELMANN, BODIL</style></author><author><style face="normal" font="default" size="100%">AL-MUDERIS, OMAR</style></author><author><style face="normal" font="default" size="100%">MESSIOU, CHRISTINA</style></author><author><style face="normal" font="default" size="100%">THWAY, KHIN</style></author><author><style face="normal" font="default" size="100%">MIAH, AISHA</style></author><author><style face="normal" font="default" size="100%">ZAIDI, SHANE</style></author><author><style face="normal" font="default" size="100%">CONSTANTINIDOU, ANASTASIA</style></author><author><style face="normal" font="default" size="100%">BENSON, CHARLOTTE</style></author><author><style face="normal" font="default" size="100%">GENNATAS, SPYRIDON</style></author><author><style face="normal" font="default" size="100%">JONES, ROBIN L.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">239-245</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.11766</style></doi><volume><style face="normal" font="default" size="100%">34</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Low-grade fibromyxoid sarcoma (LGFMS) is a rare sarcoma subtype with a generally indolent pattern of clinical behaviour, but treatments for advanced disease are limited. Patients and Methods: A retrospective search of a prospectively maintained institutional database identified 102 patients treated from December 1994 to August 2018. We evaluated the outcome of patients and the efficacy and safety of non-surgical therapies in LGFMS. Results: Ninety-four out of 102 (92.2%) underwent primary resection, seven (6.9%) were treated with systemic therapy and one (1.0%) is currently being treated with pre-operative radiotherapy. The RECIST 1.1 response rate to first-line chemotherapy was 0%, and median progression-free survival was 1.84 months (95% confidence intervaI=0.10-3.6 months). Conclusion: Conventional systemic therapy has limited efficacy in advanced LGFMS.</style></abstract></record></records></xml>